U.S. Tech Hardware Stock News

NYSE:NRP
NYSE:NRPOil and Gas

Is It Time To Reassess Natural Resource Partners (NRP) After Its Multi Year Rally

If you are looking at Natural Resource Partners and wondering whether the current price reflects its true value, this article will walk you through what the numbers are really saying. The stock closed at US$121.05, with returns of a 1.8% decline over 7 days, 6.0% over 30 days, 16.4% year to date, 19.6% over 1 year and a very large gain over 5 years. This naturally raises questions about how the current price stacks up against fundamentals. Recent interest in Natural Resource Partners has...
NasdaqGS:FIGR
NasdaqGS:FIGRConsumer Finance

Figure Technology Solutions (FIGR) 31% Net Margin Reinforces Bullish Profitability Narrative

Figure Technology Solutions (FIGR) FY 2025 Earnings Snapshot Figure Technology Solutions (FIGR) has capped FY 2025 with Q4 revenue of US$135.6 million and basic EPS of US$0.07, alongside trailing twelve month revenue of US$432.1 million and EPS of US$1.17 that put the latest figures into a fuller context. The company has seen quarterly revenue move from US$67.9 million in Q1 2025 to US$90.0 million in Q2, US$138.5 million in Q3 and US$135.6 million in Q4, while basic EPS has ranged from a...
NYSE:BKU
NYSE:BKUBanks

A Look At BankUnited (BKU) Valuation After Solid Results And Slower Net Interest Income Growth

Recent commentary around BankUnited (BKU) focuses on its solid quarterly results, which have supported recent share price gains, while also highlighting slower net interest income growth and the possibility of a less efficient cost base ahead. See our latest analysis for BankUnited. At a latest share price of $46.70, the 1 day and 7 day share price returns of 5.62% and 6.73% declines contrast with a 90 day share price return of 8.08% and a 1 year total shareholder return of 28.47%. This...
NYSE:BFLY
NYSE:BFLYMedical Equipment

Assessing Butterfly Network’s Valuation After Record Q4 Growth And First Positive Operating Cash Flow

Butterfly Network (BFLY) is back on investors’ radar after reporting record fourth quarter revenue, 41% year-over-year growth and its first quarter of positive operating cash flow, supported by its Butterfly Embedded platform and Midjourney partnership. See our latest analysis for Butterfly Network. The share price has been volatile around the recent earnings and guidance, with a 27.18% 7 day share price return reversing sharply into an 18.84% 1 day decline. At the same time, the 1 year total...
NYSE:OXY
NYSE:OXYOil and Gas

Is Occidental Petroleum (OXY) Pricing Reflect Long Term Value After Mixed Share Performance

If you are wondering whether Occidental Petroleum's current share price really reflects what you are getting for your money, this article walks through the numbers so you can judge the value for yourself. The stock last closed at US$53.08, with returns of 2.4% over 7 days, 18.4% over 30 days, 25.2% year to date, 11.1% over 1 year, negative 8.9% over 3 years and 80.4% over 5 years. This gives you a mixed picture to keep in mind as you weigh the valuation. Recent coverage of Occidental has...
NYSE:OTIS
NYSE:OTISMachinery

A Look At Otis Worldwide (OTIS) Valuation After Launch Of Arise MOD Elevator Modernization Packages

Otis Worldwide (OTIS) has introduced its Arise MOD Prime and Arise MOD Plus elevator modernization packages in North America, giving building owners more choice over how they update low to mid rise residential and commercial elevators. See our latest analysis for Otis Worldwide. At a share price of US$92.56, Otis has a 30 day share price return of 4.47%. Its 1 year total shareholder return shows a 5.52% decline, which contrasts with a 54.07% total shareholder return over five years and...
NasdaqCM:ABTC
NasdaqCM:ABTCSoftware

American Bitcoin (ABTC) Revenue Surge With FY 2025 Loss Tests Bullish Growth Narratives

American Bitcoin (ABTC) has closed out FY 2025 with Q4 revenue of US$78.3 million and a basic EPS loss of US$0.06, alongside trailing twelve month revenue of US$185.2 million and EPS of US$0.17. Over the past few quarters the company has seen revenue move from US$11.6 million in Q3 2024 to US$12.3 million in Q1 2025, US$30.3 million in Q2 2025, US$64.2 million in Q3 2025 and US$78.3 million in Q4 2025, while quarterly EPS has ranged from a loss of US$1.99 in Q1 2025 to a profit of US$0.06 in...
NasdaqGS:CHDN
NasdaqGS:CHDNHospitality

Is Churchill Downs’ Mixed 2025 Earnings and New Marshall Yards Venue Altering The Investment Case For Churchill Downs (CHDN)?

Churchill Downs Incorporated recently reported fourth-quarter and full-year 2025 results, with revenue rising to US$665.9 million in the quarter and US$2.93 billion for the year, while net income and earnings per share eased compared with 2024. Alongside earnings, the company continued to build out its historical horse racing footprint, including the February 2026 opening of the Marshall Yards Racing & Gaming venue in Kentucky, underlining management’s focus on expanding higher-margin racing...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

Monster Beverage (MNST) Margin Expansion Reinforces Bull Narratives Despite Rich P/E

Monster Beverage (MNST) closed out FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.46, alongside trailing twelve month revenue of US$8.3 billion and EPS of US$1.95 that followed earnings growth of 26.3% over the last year. Over recent periods, the company has seen quarterly revenue move from US$1.9 billion in Q3 2024 to US$2.0 billion in Q4 2024, then to US$1.9 billion in Q1 2025 and US$2.1 billion in both Q2 and Q4 2025, while basic EPS shifted from US$0.38 in Q3...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts. Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...
NYSE:BRSL
NYSE:BRSLHospitality

Brightstar Lottery Board Shifts Test Capital Returns And Italy Growth Plan

Brightstar Lottery (NYSE:BRSL) has appointed Mariangela Zappia, an international diplomat, as an independent director to its board. The company has announced that CFO Max Chiara will not stand for board re election, with his departure expected after the upcoming shareholder meeting. Brightstar recently secured a nine year renewal of the Italy Lotto licence, supporting a multiyear capital allocation plan and expansion initiatives. Brightstar Lottery, listed on the NYSE under ticker BRSL,...
NYSE:FR
NYSE:FRIndustrial REITs

A Look At First Industrial Realty Trust’s Valuation After Land & Buildings’ Activist Letter And Board Challenge

Why the activist letter matters for First Industrial Realty Trust (FR) On February 26, Land & Buildings Investment Management publicly challenged First Industrial Realty Trust (FR), criticizing its boardroom culture and urging changes it says are needed to address the REIT’s trading discount and unlock more value. See our latest analysis for First Industrial Realty Trust. At a share price of US$63.14, First Industrial Realty Trust has logged an 11.03% 1 month share price return and a 14.42% 1...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Olema Pharmaceuticals (OLMA) Valuation Check After Recent Share Price Volatility

Olema Pharmaceuticals (OLMA) has been drawing attention after recent share price swings, with the stock at US$24.20 and mixed returns over the past month, past 3 months, and year to date, prompting fresh investor scrutiny. See our latest analysis for Olema Pharmaceuticals. While the recent 1 day and 30 day share price returns show modest declines from US$24.20, the very large 1 year and 3 year total shareholder returns suggest earlier optimism around Olema Pharmaceuticals is now being...
NYSE:ECG
NYSE:ECGConstruction

Why Everus Construction Group (ECG) Is Up 11.8% After Record 2025 Results And Higher 2026 Guidance

In February 2026, Everus Construction Group, Inc. reported fourth-quarter 2025 sales of US$1,011.47 million and net income of US$55.28 million, alongside full-year 2025 sales of US$3.75 billion and net income of US$201.77 million, and issued 2026 revenue guidance of US$4.1 billion to US$4.2 billion. Management also underscored that Everus is actively pursuing accretive acquisitions, backed by a strong balance sheet, expanded corporate development capabilities and a broader M&A pipeline...
NYSE:DUK
NYSE:DUKElectric Utilities

A Look At Duke Energy (DUK) Valuation After Nuclear Reliability Milestone And Analyst Upgrades

Analyst reaction to Duke Energy’s nuclear reliability milestone Duke Energy (DUK) has drawn fresh attention after reporting record 2025 nuclear fleet reliability of 96.9%, tied to roughly US$600 million in federal nuclear production tax credits passed through to customers. Recent analyst commentary has linked this operational update to a stronger earnings outlook and increased confidence in the company’s long term execution. This has prompted many investors to take a closer look at the...
NYSE:ESTC
NYSE:ESTCSoftware

Elastic ESTC Swings To Q3 Profit Challenging Persistent Loss Making Narrative

Q3 2026 results set up a cleaner earnings story for Elastic (ESTC) Elastic (ESTC) has just posted Q3 2026 revenue of US$449.9 million with basic EPS of US$0.07, alongside trailing twelve month revenue of about US$1.7 billion and a basic EPS loss of US$0.80, giving investors a clearer read on both recent momentum and the still negative full year earnings base. The company has seen quarterly revenue move from US$365.4 million in Q2 2025 to US$449.9 million in Q3 2026, while basic EPS has...
NYSE:LEN
NYSE:LENConsumer Durables

The Bull Case For Lennar (LEN) Could Change Following New Shareholder Push On Voting Rights

In February 2026, Lennar disclosed that the Illinois State Treasurer submitted a shareholder proposal seeking vote-by-share-class reporting, while another proposal urged the company to move toward a one-share, one-vote structure, ahead of its April 8, 2026 annual meeting. These governance-focused proposals highlight growing investor pressure for greater transparency and voting equality at Lennar, even as the company continues expanding communities like Cedar Springs in Alabama. We’ll now...
NYSE:BURL
NYSE:BURLSpecialty Retail

Burlington’s 2026 Expansion Plans Test Valuation And Debt Profile

Burlington Stores (NYSE:BURL) plans to open 110 net new stores in 2026, ahead of earlier expectations. The company is also expanding its corporate office footprint in New York to support a larger organization. These moves reflect management's intent to scale operations and reinforce Burlington's long term growth plans. Burlington Stores comes into this announcement with its shares at $306.62 and a 1 year return of 23.0%. Over 3 years the stock has returned 41.8%, and over 5 years 9.8%,...
NasdaqCM:NUTX
NasdaqCM:NUTXHealthcare

Nutex Health (NUTX) Is Up 9.3% After Profitability And Valuation Analysis Sparks Investor Interest

Recent analysis of Nutex Health’s hybrid model of micro-hospitals, hospital management services, and population health programs highlighted strong profitability metrics and claims of deep undervaluation, drawing fresh investor attention in the past week. An interesting angle is the company’s high free cash flow conversion, which some commentators argue could support a meaningful reassessment of its valuation if operating performance holds. We’ll now examine how Nutex Health’s highlighted...
NasdaqGS:ABCL
NasdaqGS:ABCLLife Sciences

AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering

AbCellera Biologics Inc. has reported its full-year 2025 results, with revenue rising to US$75.13 million and net loss easing to US$146.41 million, while also filing a US$45.54 million shelf registration for 15,030,034 common shares tied to an employee share offering. Alongside these financials, AbCellera’s shift into a clinical-stage biotech with advancing programs ABCL635 and ABCL575 and a nearly completed manufacturing facility signals a business model increasingly centered on internal...
NYSE:INSW
NYSE:INSWOil and Gas

A Look At International Seaways (INSW) Valuation After Record Earnings And Largest Ever Dividend

International Seaways (INSW) is back in focus after reporting record fourth quarter net income and pairing those results with its largest ever quarterly dividend, a combined US$2.15 per share. See our latest analysis for International Seaways. The latest earnings and dividend news has arrived after a strong run in the shares, with a 30 day share price return of 26.6% and a year to date gain of 60.74%. That move sits on top of a very large 1 year total shareholder return of 143.19% and a 5...
NYSE:ARLO
NYSE:ARLOElectronic

Arlo Technologies (ARLO) Earnings Turn Positive Challenging Skeptical Profitability Narratives

Arlo Technologies (ARLO) closed out FY 2025 with Q4 revenue of US$141.3 million and basic EPS of US$0.05, alongside net income of US$5.8 million. The trailing 12 month line shows revenue of US$529.3 million and basic EPS of US$0.14 as the business moves further into consistent profitability. Over the past six quarters, the company has seen revenue range from US$119.1 million to US$141.3 million per quarter, with basic EPS shifting from a loss of US$0.05 in late 2024 to positive contributions...
NYSE:HLX
NYSE:HLXEnergy Services

Helix Energy Solutions Group (HLX) Valuation After Record Q4 Revenue And New Multiyear Contract Wins

Helix Energy Solutions Group (HLX) is back in focus after reporting its highest fourth quarter revenue since 2013, positive free cash flow, and year end cash and liquidity that support recently secured multiyear contracts. See our latest analysis for Helix Energy Solutions Group. Those results come after a busy period, with Helix Energy Solutions Group reporting full year 2025 earnings, recording a US$18.06 million long lived asset impairment, completing its share repurchase program, and...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Is Oddity Tech (ODD) Now An Opportunity After A 70% Year To Date Share Price Fall

If you are wondering whether Oddity Tech is now a bargain or a value trap, a closer look at how its current share price lines up with its fundamentals can help frame that question. The stock has seen large price swings recently, with a 7 day return of 63.2% decline, a 30 day return of 64.8% decline, and a year to date return of 70.2% decline, while the 1 year return sits at 75.3% decline from the current last close of US$11.77. These moves have prompted renewed attention on the business, as...